Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Global Market Value Of The Gout Therapeutics Industry In 2025?
The gout therapeutics market size has shown rapid expansion in recent years. It is forecast to increase from $2.88 billion in 2024 to $3.22 billion in 2025, achieving a compound annual growth rate (CAGR) of 11.9%. The market’s past growth can be attributed to several factors including the rising prevalence of gout, changes in lifestyle and dietary habits, the widespread presence of high blood pressure and diabetes, advancements in xanthine oxidase inhibitors, and various patient education programs.
The gout therapeutics market is anticipated to experience substantial growth in the near future. By 2029, its valuation is projected to reach $5 billion, expanding at a compound annual growth rate (CAGR) of 11.7%. This growth over the forecast period is attributed to rising healthcare expenditure, advancements in drug delivery systems, the emergence of novel therapies, government initiatives focused on chronic disease management, and the influence of patient advocacy and support groups. Major trends during this period encompass innovative drug development, new drug approvals, personalized medicine approaches, telehealth services for gout management, and research in urate-lowering therapies.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12118&type=smp
Which Drivers Are Shaping The Gout Therapeutics Industry’s Market Share?
The increasing prevalence of gout is anticipated to drive expansion within the gout therapeutics market in the future. Gout is defined as an inflammatory arthritis condition characterized by pain and swelling in joints. Gout therapeutics are designed to manage and alleviate discomfort, inflammation, and sensitivity in affected joints. Given this, the growing incidence of gout is consequently projected to enhance sales within the gout therapeutics market. For instance, in June 2024, the Australian Institute of Health and Welfare, a US-based government agency, reported that gout was identified as an underlying and contributing factor in 573 deaths in Australia in 2022, corresponding to 2.2 deaths per 100,000 individuals. Therefore, the rising incidence of gout stands as a significant factor propelling the growth of the gout therapeutics market.
What Are The Different Segment Classifications Within The Gout Therapeutics Market?
The gout therapeuticsmarket covered in this report is segmented –
1) By Type: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs); Corticosteroid; Diuretics
2) By Treatment: Xanthine Oxidase Inhibitor; Uricosuria Medication
3) By Disease Condition: Acute; Chronic
4) By End-Users: Hospitals; Specialty Clinics; Other End Users
Subsegments:
1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Traditional NSAIDs; Selective COX-2 Inhibitors
2) By Corticosteroid: Oral Corticosteroids; Injectable Corticosteroids
3) By Diuretics: Thiazide Diuretics; Loop Diuretics
What Are The Major Trends Driving The Growth Of The Gout Therapeutics Market?
Product innovation is a significant trend gaining traction in the gout therapeutics market. Leading companies operating in the gout therapeutics market are developing advanced treatments to maintain their market position. For instance, in August 2022, Synlogic Inc., a US-based pharmaceutical company, unveiled SYNB2081, a new drug candidate for gout treatment. SYNB2081 functions as a synthetic biotic specifically engineered to lower uric acid. This compound represents the second clinical drug candidate developed through a research collaboration between Synlogic and Ginkgo, a US-based biotech company.
Which Key Market Players Are Investing In Expansion And Innovation Of Gout Therapeutics Market?
Major companies operating in the gout therapeutics market include Sanofi-Aventis, AstraZeneca plc, LG Chem Ltd., GlaxoSmithKline Plc, Takeda Pharmaceuticals Co. Ltd., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Sandoz, Eisai Co. Ltd., Horizon Pharma Plc, Jiangsu HengRui Medicine Co. Ltd., Hikma Pharmaceuticals plc, Swedish Orphan Biovitrum AB, JW Pharmaceutical Corp, Lannett Company Inc, BioCryst Pharmaceuticals Inc., Selecta Biosciences Inc., Rigel Pharmaceuticals Inc., CymaBay Therapeutics Inc., GeneScience Pharmaceuticals Co. Ltd., Shanton Pharma
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/gout-therapeutics-global-market-report
Which Region Is Expected To Witness The Fastest Growth In The Gout Therapeutics Market?
North America was the largest region in the gout therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gout therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Gout Therapeutics Market Report:
https://www.thebusinessresearchcompany.com/customise?id=12118&type=smp
Browse Through More Reports Similar to the Global Gout Therapeutics Market 2025, By The Business Research Company
Electricity And Signal Testing Instruments Global Market Report 2025
Non Animal Alternatives Testing Global Market Report 2025
Pharmaceutical Sterility Testings Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model